Parse Biosciences announced a collaboration with Codebreaker Labs to combine engineered variant libraries with high‑throughput single‑cell transcriptomics to experimentally map how genetic variants affect cellular states. The platform aims to scale variant‑effect data for target discovery, AI training and precision clinical‑trial design. Separately, Swedish spinout Epigenovo published proof‑of‑concept for scFFPE‑ATAC, a workflow that profiles chromatin accessibility at single‑cell resolution in formalin‑fixed, paraffin‑embedded (FFPE) tissues—a class of clinical specimens previously difficult to analyze at single‑cell scale. Epigenovo is raising commercialization funding for kitted assays and services. Together these advances address two bottlenecks for clinical genomics: the ability to interrogate the effects of variants in relevant human cell types at scale, and the capacity to extract single‑cell epigenetic information from archived clinical tissue.